News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AB Science (AB.PA) Announces Recruitment of First Patient in Phase 2B/3 Study of Masitinib in Rheumatoid Arthritis


8/3/2011 10:01:26 AM

PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today the recruitment of the first patient in the phase 2b/3 study of masitinib in rheumatoid arthritis.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES